CB1509

CHO-K1 IndCLDN18.2

£5,000.00
£5,000.00
Tax included.
In Stock

CHO-K1 IndCLDN18.2 is an IndEx-2 stable cell line inducibly expressing full length human CLDN18.2. 

IndEx-2 is RoukenCells' proprietary inducible expression system that enables precise, dose-dependent control of one or two target antigens within your chosen cell line. Using orthogonal chemically induced proximity switches, antigen expression can be independently tuned across a biologically relevant range, creating custom cell models for target validation, assay development and therapeutic screening.

Download our technical presentation here for more information and case studies.

FOR RESEARCH USE ONLY

Packaging of Rouken Cells product on a white background
  • Packaging of Rouken Cells product on a white background
Packaging of Rouken Cells product on a white background
Specification
Inducible Receptor
CLDN18.2
CD Designation
N/A
Gene name
CLDN18.2
Aliases
CLDN18.2, Claudin-18 isoform 2
Uniprot ID
P56856
Receptor Species
Homo sapiens
Cell Line Background
CHO-K1
Target Information and Further Details
CLDN18.2 is a specific isoform of the claudin-18 gene product, produced by alternative splicing of CLDN18. While claudin-18 is normally expressed in the gastric mucosa and lung alveoli, the 18.2 isoform is selectively expressed in differentiated epithelial cells of the gastric mucosa. In cancer, CLDN18.2 is aberrantly exposed due to disruption of cell polarity and tight junctions, and is retained in a subset of gastric, pancreatic, esophageal, and other gastrointestinal adenocarcinomas. Importantly, it remains highly tumour-specific, making it a promising therapeutic target. The leading clinical agent targeting CLDN18.2 is zolbetuximab, a monoclonal antibody that mediates tumour cell killing via antibody-dependent cellular cytotoxicity (ADCC). Zolbetuximab has shown promising results in gastric and gastroesophageal cancers and is currently in advanced-phase clinical trials. Other therapeutic approaches under investigation include CAR-T cell therapies and bispecific antibodies targeting CLDN18.2. Its restricted normal tissue expression and prevalent tumour expression profile make CLDN18.2 a particularly attractive target in oncology.
Performance Data

Figure 1 – Histograms of CLDN18.2 Induction at 0-100 µM Inducer.

Figure 2 – Quantification of CLDN18.2 Induction at 0-100 µM Inducer.

* Cells were then stained with a labelled antibody and expression levels quantified using a bead-based quantification kit. Specific induction conditions should be further defined by the user. Cell line suitable for preclinical research and development use only.

Shipping Details

Supplied as 1 vial of >3 million viable cells.

* Please note that US import permits for CHO-K1 cell products are the responsibility of the US-based recipient/importer. RoukenCells is happy to provide supporting documentation (e.g. product descriptions and noninfectious statements) to assist with the import process.

Cell Line Datasheet

Access detailed product specifications, user guides and technical documentation in PDF format.

Download PDF

Related products

Take a moment to explore selections tailored just for you.

Explore Now